Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities

Table 2 Prevalence ratios of history of hepatitis C virus testing by substance use pattern in rural opioid initiative cohort, 2018–2020

Substance Use Pattern, past 30 days	Unadjusted		Adjusted
	Unadjusted		DAG-Informed Model²¹
	PR	95% CI	aPR	95% CI
Other drug use (no opioid or stimulant use)	referent		referent
Opioid use without stimulant use	0.78	(0.60, 1.01)	0.80	(0.63, 1.02)
Stimulant use without opioid use	0.88	(0.67, 1.14)	0.88	(0.69, 1.13)
Opioid and stimulant use	0.90	(0.70, 1.15)	0.93	(0.74, 1.16)

PR, Prevalence Ratio; aPR, adjusted Prevalence Ratio
1. Adjusted for age, binge drinking in the past 30 days, education, gender, homelessness, race, relationship status, and transportation

ISSN: 1477-7517